Opinions posted by MikeHavRx

Feb 05 at 7:40AM (EST) (By MikeHavRx)

$GOOG - break of 525

As per yesterday's note - GOOG has broken 525 - next target 500 I own GOOG Puts

Feb 05 at 7:32AM (EST) (By MikeHavRx)

Buying $EDZ Emerging Markets Bearish Play

I am buying shares of EDZ - a bearish play on emerging markets with 3X leverage

Feb 04 at 1:21PM (EST) (By MikeHavRx)

Updated Executive Summary for Access Pharma (OTC: ACCP.OB)

Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and othe...

Feb 04 at 5:20AM (EST) (By MikeHavRx)

Google ($GOOG) 500?

Looks like Google heading to test of 500 - confirmed on break of 525

Feb 04 at 4:15AM (EST) (By MikeHavRx)

Will Dow hold 10,000?

Barring any major upside employmet surprises tomorrow, it seems inevitable that we break 10,000 and test support between 9600 and 9800 shortly thereafter.  200 Day Moving average is around 9600 &​nbsp;  seems like only logical next support ...

Feb 02 at 11:59AM (EST) (By MikeHavRx)

Waste2Energy: Making Electricity from a Town’s Garbage

  Waste2Energy: Making Electricity from a Town's Garbage   The average American generates nearly a ton of trash each year. Each suburban home annually produces 15 pounds of hazardous household waste including medications, paints, solvents and a...

Jan 27 at 3:32AM (EST) (By MikeHavRx)

Keryx / Aeterna Drug Shows Promise in Late-Stage Colon Cancer Patients

The ProActive News Room website for Keryx Biopharma (NASDAQ: KERX) has been updated to include the Company's most recent corporate presentation and the GI-ASCO 2010 poster presentation from last weekend. In the randomized Phase 2 trial, perifosine + capec...

Jan 23 at 6:29AM (EST) (By MikeHavRx)

Mike Havrilla (@mikehavrilla) on Twitter

My Twitter updates include notifications and web links to new investing articles, research reports, FDA Calendar updates, bio-medical industry news, MarketGuru.com virtual investing activity, and more. Mike Havrilla (@mikehavrilla) on Twitter:htt​p://twitt...

Jan 19 at 3:21AM (EST) (By MikeHavRx)

Access Pharma's Drug Delivery Technology is a Stealth Asset

Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs. The BioMedReports.com research downloads section and the ProActive News Room website for Access both contain the mo...

Jan 17 at 7:04AM (EST) (By MikeHavRx)

Healthcare Conference Update: A New Strategy for IMUC

I had the opportunity last week to discuss the updated strategy and expected milestones for ImmunoCellular Therapeutics (OTC: IMUC.OB) in 2010 and beyond with CEO, Manish Singh, following the conclusion of the OneMed, JP Morgan, and other healthcare conf...